// App-Quantinova.ai

4515 : Updated efficacy from IMvigor210: Atezolizumab in platinum treated locally advanced/metastatic urothelial carcinoma (mUC).

Researchers

Presenter

  • Robert Dreicer

Principal Investigators

  • Thomas W. Flaig

  • Enrique Grande

  • Ani Sarkis Balmanoukian

  • Gunhild von Amsberg

  • Christine Theodore

  • Simon Chowdhury

  • Sergio Bracarda

  • Jessica Mary Clement

  • Evan Y. Yu

  • Arash Rezazadeh Kalebasty

  • Guenter Niegisch

  • Stephane Culine

  • Michael S. Gordon

  • Na Cui

  • Sanjeev Mariathasan

  • Fatema A. Legrand

  • Oyewale O. Abidoye

  • Daniel Peter Petrylak

Medical Centers

  • University of Virginia school of medicine, Charlottesville, VA

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • University of Colorado Cancer Center, Aurora, CO

  • Medical Oncology Department. Hospital Universitario La Paz, Madrid, Spain

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Hospital Foch, Suresnes, France

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Medical Oncology, Ospedale San Donato USL8, Istituto Toscano Tumori, Arezzo, Italy

  • University of Connecticut Health Center Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Norton Cancer Institute, Louisville, KY

  • Department of Urology, Heinrich-Heine-University, Duesseldorf, Germany

  • Hospital Saint Antoine, Paris, France

  • Pinnacle Oncology Hematology/HonorHealth Research Institute, Scottsdale, AZ

  • Genentech, Inc., South San Francisico, CA

  • Roche/Genentech, South San Francisco, CA

  • Genentech, San Francisco, CA

  • Yale University, New Haven, CT

Locations

  • Italy

  • Spain

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02589717

  • NCT02108652

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved